Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?

Key Takeaways PFE beat Q4 earnings & sales estimates, but revenues fell 3% operationally due to sharp COVID product declinePFE reported positive phase IIb obesity data for PF'3944, strengthening its pipeline after the Metsera buyout.Pfizer's 2026 outlook indicates lower revenues and EPS, pressured by COVID erosion, LOEs and higher costs.Pfizer’s (PFE)  fourth-quarter results were strong as it beat estimates for both earnings and sales. Total revenues declined 3% on an operational basis due to a 40% decline ...